Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION A CRL citing manufacturing, not efficacy put RWE protocol that may not meet regulator expectations in front of RWE evidence-strategy director in a biologics company planning a biosimilar pathway. This Pharma & Life Sciences / CMC and Development Pathways close is to drop a secondary from RWE protocol that may not meet regulator expectations, and the live options are Proceed under protocol, Pause the pathway, Escalate safety review.

DECISION RWE evidence-strategy director in a biologics company planning a biosimilar pathway must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using RWE protocol that may not meet regulator expectations after a CRL citing manufacturing, not efficacy.

HYPOTHESES TO TEST 1. A CRL citing manufacturing, not efficacy is noise around an already-controlled CMC and Development Pathways process in a biologics company planning a biosimilar pathway, given RWE protocol that may not meet regulator expectations. 2. A CRL citing manufacturing, not efficacy is the event in RWE protocol that may not meet regulator expectations that forces Proceed under protocol for RWE evidence-strategy director under Pharma & Life Sciences. 3. RWE protocol that may not meet regulator expectations shows a one-file miss after a CRL citing manufacturing, not efficacy, not a CMC and Development Pathways program failure. 4. RWE protocol that may not meet regulator expectations cannot decide to drop a secondary yet after a CRL citing manufacturing, not efficacy; hold is the only Pharma & Life Sciences close a biologics company planning a biosimilar pathway can defend.

ANALYSIS REQUIRED 1. Separate an isolated adverse event from a systemic quality issue. 2. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 3. Check whether RWE protocol that may not meet regulator expectations supports the labeled claim RWE evidence-strategy director would keep. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read RWE protocol that may not meet regulator expectations against a CRL citing manufacturing, not efficacy and write the one fact that would move to drop a secondary for RWE evidence-strategy director.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (RWE protocol that may not meet regulator expectations after a CRL citing manufacturing, not efficacy). Lead with the Pharma & Life Sciences option RWE protocol that may not meet regulator expectations can support after a CRL citing manufacturing, not efficacy, then the two facts that force it, then the Monday action for RWE evidence-strategy director in a biologics company planning a biosimilar pathway.